|
|
Blood, 1 October 2007, Vol. 110, No. 7, pp. 2586-2592.
Prepublished online as a Blood First Edition Paper on June 18, 2007; DOI 10.1182/blood-2007-05-088443.
 Previous Article | Next Article 
Submitted May 7, 2007
Accepted June 11, 2007
New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering mutliple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells
Ernesto Perez-Persona, Maria-Belen Vidriales, Gema Mateo, Ramon Garcia-Sanz, Maria-Victoria Mateos, Alfonso Garcia de Coca, Josefina Galende, Guillermo Martin-Nunez, Jose M Alonso, Natalia de las Heras, Jose M Hernandez, Alejandro Martin, Consuelo Lopez-Berges, Alberto Orfao, and Jesus F San Miguel*
Department of Hematology, University Hospital, Salamanca, Spain
Centro de Investigacion del Cancer, Universidad de Salamanca/ CSIC, Salamanca, Spain
Department of Hematology, University Hospital, Valladolid, Spain
Department of Hematology, Hospital Comarcal del Bierzo, Ponferrada, Leon, Spain
Department of Hematology, Hospital Nuestra Senora del Puerto, Plasencia, Caceres, Spain
Department of Hemtology, Hospital Rio Carrion, Palencia, Spain
Department of Hematology, Complejo Hospitalario, Leon, Spain
Department of Hematology, General Hospital, Segovia, Spain
Department of Hematology, Hospital Virgen de la Concha, Zamora, Spain
Deparment of Cytometry, University of Salamanca, Salamanca, Spain
* Corresponding author; email: sanmigiz{at}gugu.usal.es.
Monoclonal gammopathy of uncertain significance (MGUS) and smoldering Multiple Myeloma (SMM) are plasma cell disorders with a risk of progression around 1% and 10% per year, respectively. We have previously shown that the proportion of BM aberrant plasma cells within the BMPC (bone marrow plasma cell) compartment (aPC/BMPC) assessed by FlowCytometry contribute to differential diagnosis between MGUS and MM. The goal of the present study was to investigate this parameter as a marker for risk of progression in MGUS (n=407) and SMM (n=93). Patients with a marked predominance of aPC/BMPC ( 95%) at diagnosis displayed a significantly higher risk of progression both in MGUS and SMM (p< 0.001). Multivariate analysis for progression free survival (PFS) selected the % aPC/BMPC (95%) as the most important independent variable in both entities, together with DNA aneuploidy and immunoparesis for MGUS and SMM, respectively. Using these independent variables, we have identified three risk categories in MGUS (PFS at 5 years of 2%, 10% and 46%, respectively (p<0.001)) and SMM patients (PFS at 5 years of 4%, 46%, and 72%, respectively (p<0.001)). Our results show that multiparameter FC evaluation of BMPC at diagnosis is a valuable tool that could help to individualize the follow-up strategy for MGUS and SMM patients.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
Related Article in Blood Online:
-
Progression risk for MGUS and SMM
- Philip Greipp
Blood 2007 110: 2226.
[Full Text]
[PDF]
This article has been cited by other articles:
|
|
|
|
 
G. Mateo, M. A. Montalban, M.-B. Vidriales, J. J. Lahuerta, M. V. Mateos, N. Gutierrez, L. Rosinol, L. Montejano, J. Blade, R. Martinez, et al.
Prognostic Value of Immunophenotyping in Multiple Myeloma: A Study by the PETHEMA/GEM Cooperative Study Groups on Patients Uniformly Treated With High-Dose Therapy
J. Clin. Oncol.,
June 1, 2008;
26(16):
2737 - 2744.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. C. Rawstron, A. Orfao, M. Beksac, L. Bezdickova, R. A. Brooimans, H. Bumbea, K. Dalva, G. Fuhler, J. Gratama, D. Hose, et al.
Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders
Haematologica,
March 1, 2008;
93(3):
431 - 438.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Blade and L. Rosinol
SMM: toward better predictors of progression
Blood,
January 15, 2008;
111(2):
479 - 480.
[Full Text]
[PDF]
|
|
|
| |
